Emetine blocks DNA replication via proteosynthesis inhibition not by targeting Okazaki fragments.
Journal
Life science alliance
ISSN: 2575-1077
Titre abrégé: Life Sci Alliance
Pays: United States
ID NLM: 101728869
Informations de publication
Date de publication:
09 09 2022
09 09 2022
Historique:
received:
14
06
2022
revised:
30
08
2022
accepted:
30
08
2022
entrez:
19
10
2022
pubmed:
20
10
2022
medline:
22
10
2022
Statut:
epublish
Résumé
DNA synthesis of the leading and lagging strands works independently and cells tolerate single-stranded DNA generated during strand uncoupling if it is protected by RPA molecules. Natural alkaloid emetine is used as a specific inhibitor of lagging strand synthesis, uncoupling leading and lagging strand replication. Here, by analysis of lagging strand synthesis inhibitors, we show that despite emetine completely inhibiting DNA replication: it does not induce the generation of single-stranded DNA and chromatin-bound RPA32 (CB-RPA32). In line with this, emetine does not activate the replication checkpoint nor DNA damage response. Emetine is also an inhibitor of proteosynthesis and ongoing proteosynthesis is essential for the accurate replication of DNA. Mechanistically, we demonstrate that the acute block of proteosynthesis by emetine temporally precedes its effects on DNA replication. Thus, our results are consistent with the hypothesis that emetine affects DNA replication by proteosynthesis inhibition. Emetine and mild POLA1 inhibition prevent S-phase poly(ADP-ribosyl)ation. Collectively, our study reveals that emetine is not a specific lagging strand synthesis inhibitor with implications for its use in molecular biology.
Identifiants
pubmed: 36260751
pii: 5/12/e202201560
doi: 10.26508/lsa.202201560
pmc: PMC9463495
pii:
doi:
Substances chimiques
Okazaki fragments
0
Emetine
X8D5EPO80M
DNA, Single-Stranded
0
DNA
9007-49-2
Chromatin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2022 Lukac et al.
Références
Nature. 2018 Jul;559(7713):279-284
pubmed: 29950726
Cancer Res. 2020 Feb 1;80(3):394-405
pubmed: 31776133
Exp Cell Res. 2022 Aug 1;417(1):113163
pubmed: 35447104
Cell Cycle. 2018;17(5):568-579
pubmed: 28976232
J Cell Biol. 2014 Jan 6;204(1):29-43
pubmed: 24379417
EMBO J. 2009 Sep 2;28(17):2601-15
pubmed: 19629035
Trends Genet. 2019 Jun;35(6):412-422
pubmed: 31036342
Mol Cell. 2018 Jul 19;71(2):319-331.e3
pubmed: 29983321
Nat Commun. 2020 May 1;11(1):2147
pubmed: 32358495
Nat Rev Mol Cell Biol. 2017 Oct;18(10):610-621
pubmed: 28676700
Cell Rep. 2020 Feb 18;30(7):2416-2429.e7
pubmed: 32075739
J Biol Chem. 2009 Feb 13;284(7):4041-5
pubmed: 18835809
Cell. 1989 Jun 16;57(6):909-20
pubmed: 2544294
Cell. 1976 Oct;9(2):213-9
pubmed: 975243
Proc Natl Acad Sci U S A. 1966 Dec;56(6):1867-74
pubmed: 16591432
EMBO J. 1991 Dec;10(13):4351-60
pubmed: 1721870
Cell. 2013 Nov 21;155(5):1088-103
pubmed: 24267891
Mol Cell. 2021 Aug 5;81(15):3128-3144.e7
pubmed: 34216544
Front Pharmacol. 2020 Jul 02;11:1013
pubmed: 32714193
Annu Rev Biochem. 2017 Jun 20;86:417-438
pubmed: 28301743
Oncotarget. 2015 May 10;6(13):10746-58
pubmed: 25883215
J Biol Chem. 1968 Aug 10;243(15):4089-94
pubmed: 4299101
Cell Death Differ. 2022 Mar;29(3):687-696
pubmed: 34611297
J Cell Biol. 2008 Dec 29;183(7):1203-12
pubmed: 19103807